Literature DB >> 10846869

Mild cognitive impairment: transition between aging and Alzheimer's disease.

R C Petersen1.   

Abstract

The concept of the boundary between normal aging and early Alzheimer's disease is a focus of a great deal of research in the field of aging and dementia. Presumably there is a continuum of function between normality and the earliest signs of Alzheimer's disease. This transitional condition has been labeled mild cognitive impairment. Mild cognitive impairment refers to individuals who have a memory impairment greater than what one would expect for age, yet general cognitive function is preserved. Similarly activities of daily living are normal. However, the memory function of these individuals is abnormal for age and education. These subjects do not meet criteria for Alzheimer's disease. When mild cognitive impairment subjects are followed longitudinally, they tend to convert to clinically probable Alzheimer's disease as a rate of 10-15% per year. This is in contrast to normal elderly subjects who will develop Alzheimer's disease at a rate of 1-2% per year. Certain predictor variables are available to determine which subjects are more likely to progress at a rapid rate. Mild cognitive impairment is an important topic for research in aging and dementia and has also become the subject of several multicenter treatment trials.

Entities:  

Mesh:

Year:  2000        PMID: 10846869

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  112 in total

Review 1.  The impact of mild cognitive impairment on functional abilities in the elderly.

Authors:  Steven M Albert; Matias H Tabert; Alan Dienstag; Gregory Pelton; Devangere Devanand
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

2.  Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort.

Authors:  Shannon L Risacher; Li Shen; John D West; Sungeun Kim; Brenna C McDonald; Laurel A Beckett; Danielle J Harvey; Clifford R Jack; Michael W Weiner; Andrew J Saykin
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

3.  Metabolomic changes in autopsy-confirmed Alzheimer's disease.

Authors:  Rima Kaddurah-Daouk; Steve Rozen; Wayne Matson; Xianlin Han; Christine M Hulette; James R Burke; P Murali Doraiswamy; Kathleen A Welsh-Bohmer
Journal:  Alzheimers Dement       Date:  2010-11-13       Impact factor: 21.566

4.  Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease.

Authors:  Renã A S Robinson; Gururaj Joshi; Quanzhen Huang; Rukhsana Sultana; Austin S Baker; Jian Cai; William Pierce; Daret K St Clair; William R Markesbery; D Allan Butterfield
Journal:  Proteomics       Date:  2011-09-22       Impact factor: 3.984

Review 5.  Functional Disability in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

Authors:  Cutter A Lindbergh; Rodney K Dishman; L Stephen Miller
Journal:  Neuropsychol Rev       Date:  2016-07-08       Impact factor: 7.444

Review 6.  Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings.

Authors:  Meredith N Braskie; Paul M Thompson
Journal:  Trends Cogn Sci       Date:  2013-09-09       Impact factor: 20.229

7.  Tau is reduced in AD plasma and validation of employed ELISA methods.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Chuck Ziolkowski; Yushun Lin; Lisa M Sparks; Carolyn Liebsack; Sherry Johnson-Traver
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

Review 8.  Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia.

Authors:  Howard Chertkow; Fadi Massoud; Ziad Nasreddine; Sylvie Belleville; Yves Joanette; Christian Bocti; Valérie Drolet; John Kirk; Morris Freedman; Howard Bergman
Journal:  CMAJ       Date:  2008-05-06       Impact factor: 8.262

9.  Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease.

Authors:  Rukhsana Sultana; William A Banks; D Allan Butterfield
Journal:  J Neurosci Res       Date:  2010-02-15       Impact factor: 4.164

10.  NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease.

Authors:  Nicholas H Varvel; Kiran Bhaskar; Maria Z Kounnas; Steven L Wagner; Yan Yang; Bruce T Lamb; Karl Herrup
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.